It all begins with
an idea.

Protecting Intellectual Property - Building Innovative Companies - Creating American Jobs

The Medici Portfolio consists of a world-class team of patent professionals. Building on our experience within the nation's top law firms, we operate from real-life experience in patent licensing and litigation.

Michael Connelly
Chief Executive Officer and Co-founder

Michael Connelly has spent his career on the monetization of patented ideas through licensing and litigation. A former partner with McDermott Will & Emery, Michael has experienced patent litigation from both sides of the courtroom and understands the realities of the business of licensing patents. Michael founded the Medici Portfolio after seeing the disparity that inventors are faced with when trying to achieve compensation for their technological contributions. Michael earned his B.S.Eng. in Materials Science and Engineering from The Johns Hopkins University and his law degree from Georgetown University. Michael regularly speaks to various industry groups and has been quoted in the Washington Post, Philadelphia Inquirer, Pharmawire and IP360 among others.

Blair Lanier
IP Valuation and Licensing Consultant

Blair is an independent consultant for the Medici Portfolio whose broad experience in patent prosecution, litigation and asset protection gives her solid insight into portfolio monetization. Blair began her career at McDermott Will & Emery, prosecuting and litigating patents for clients ranging from sole inventors to Global 100 companies. Blair expanded her litigation experience to banking defense, giving her a unique perspective in viewing investors’ portfolios and developing strategies to protect those assets. Blair graduated Phi Beta Kappa from The Johns Hopkins University with a B.A. and M.A. in biophysics and earned her law degree from the University of Virginia. While at The Johns Hopkins University, Blair engaged in research endeavors ranging from computer programming for astronomical surveys to development of microbicidal, anti-HIV gels.